vs
Figma, Inc.（FIG）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Figma, Inc.的季度营收约是Orthofix Medical Inc.的1.2倍（$274.2M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -400.1%，领先399.1%），Figma, Inc.同比增速更快（38.0% vs 2.0%），Figma, Inc.自由现金流更多（$49.5M vs $16.8M）
Figma是主打界面设计的协作式网页应用，同时适配macOS与Windows桌面端，支持离线使用。产品聚焦UI/UX设计场景，内置矢量图形编辑、原型制作工具，主打多人实时协作，安卓及iOS移动端应用可支持用户在手机、平板上随时查看并交互预览设计原型。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FIG vs OFIX — 直观对比
营收规模更大
FIG
是对方的1.2倍
$219.9M
营收增速更快
FIG
高出36.1%
2.0%
净利率更高
OFIX
高出399.1%
-400.1%
自由现金流更多
FIG
多$32.6M
$16.8M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $274.2M | $219.9M |
| 净利润 | $-1.1B | $-2.2M |
| 毛利率 | 69.4% | 71.1% |
| 营业利润率 | -414.6% | 0.2% |
| 净利率 | -400.1% | -1.0% |
| 营收同比 | 38.0% | 2.0% |
| 净利润同比 | -6933.0% | 92.4% |
| 每股收益（稀释后） | $-2.72 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FIGOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | $274.2M | $205.6M | ||
| Q2 25 | $249.6M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | $198.6M | $196.6M | ||
| Q2 24 | $177.2M | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润FIGOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-1.1B | $-22.8M | ||
| Q2 25 | $28.2M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-15.6M | $-27.4M | ||
| Q2 24 | $-827.9M | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率FIGOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | 69.4% | 72.2% | ||
| Q2 25 | 88.8% | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | 90.6% | 68.7% | ||
| Q2 24 | 77.7% | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率FIGOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | -414.6% | -8.3% | ||
| Q2 25 | 0.8% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | -23.8% | -9.6% | ||
| Q2 24 | -504.7% | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率FIGOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -400.1% | -11.1% | ||
| Q2 25 | 11.3% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -7.9% | -13.9% | ||
| Q2 24 | -467.2% | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）FIGOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-2.72 | $-0.57 | ||
| Q2 25 | $0.00 | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | $-0.07 | $-0.71 | ||
| Q2 24 | $-4.39 | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $450.0M |
| 总资产 | $2.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FIGOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | $1.6B | $62.9M | ||
| Q2 25 | $1.6B | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | $416.1M | $30.1M | ||
| Q2 24 | $586.1M | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务FIGOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FIGOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | $1.4B | $442.5M | ||
| Q2 25 | $1.4B | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | $1.2B | $525.9M | ||
| Q2 24 | $862.4M | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产FIGOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | $2.1B | $832.6M | ||
| Q2 25 | $2.0B | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | — | $867.9M | ||
| Q2 24 | — | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比FIGOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $51.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $49.5M | $16.8M |
| 自由现金流率自由现金流/营收 | 18.0% | 7.6% |
| 资本支出强度资本支出/营收 | 0.6% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FIGOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | $51.2M | $12.4M | ||
| Q2 25 | — | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | — | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流FIGOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | $49.5M | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率FIGOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | 18.0% | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度FIGOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | 0.6% | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FIG
| Non Us | $147.4M | 54% |
| US | $126.8M | 46% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
